KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2016 - 2025)

Jazz Pharmaceuticals has reported Other Non-Current Liabilities over the past 14 years, most recently at $124.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $124.5 million for Q4 2025, up 43.76% from a year ago — trailing twelve months through Dec 2025 was $124.5 million (up 43.76% YoY), and the annual figure for FY2025 was $124.5 million, up 43.76%.
  • Other Non-Current Liabilities for Q4 2025 was $124.5 million at Jazz Pharmaceuticals, up from $108.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for JAZZ hit a ceiling of $144.0 million in Q4 2022 and a floor of $86.6 million in Q4 2024.
  • Median Other Non-Current Liabilities over the past 5 years was $123.3 million (2022), compared with a mean of $116.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: decreased 29.41% in 2024 and later soared 43.76% in 2025.
  • Jazz Pharmaceuticals' Other Non-Current Liabilities stood at $137.9 million in 2021, then increased by 4.43% to $144.0 million in 2022, then fell by 14.78% to $122.7 million in 2023, then fell by 29.41% to $86.6 million in 2024, then skyrocketed by 43.76% to $124.5 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $124.5 million (Q4 2025), $108.9 million (Q3 2025), and $93.7 million (Q2 2025) per Business Quant data.